Checkit has signed a three-year subscription contract with Biomat USA, a subsidiary of plasma and infusion medicines specialist Grifols, to provide its temperature-monitoring technology to plasma centres across the US. The vast majority of the £2.8m minimum contract value relates to upsell or new business, with further opportunities being discussed to support Grifols in Europe. This contract demonstrates Checkit’s land and expand strategy and provides support to our forecast of 56% ARR growth in FY23.
01 Feb 2022
Checkit - Three-year contract with Biomat in the US
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Checkit - Three-year contract with Biomat in the US
Checkit plc (CKT:LON) | 22.0 0 0.0% | Mkt Cap: 23.8m
- Published:
01 Feb 2022 -
Author:
Katherine Thompson -
Pages:
2
Checkit has signed a three-year subscription contract with Biomat USA, a subsidiary of plasma and infusion medicines specialist Grifols, to provide its temperature-monitoring technology to plasma centres across the US. The vast majority of the £2.8m minimum contract value relates to upsell or new business, with further opportunities being discussed to support Grifols in Europe. This contract demonstrates Checkit’s land and expand strategy and provides support to our forecast of 56% ARR growth in FY23.